Abstract:Background Less invasive surfactant administration (LISA) is a way of giving surfactant without endotracheal intubation and has shown to be promising in reducing the incidence of bronchopulmonary dysplasia (BPD) in preterm infants. However, the mechanism underlying its beneficial effect and variations in the technique of administration may prevent its widespread use. This trial aims to evaluate the effects of two methods of surfactant administration, LISA or endotracheal surfactant administration followed by low peak pressure (LPPSA) ventilation, in preterm infants with respiratory distress syndrome (RDS). Methods The L ISA O r L ow P eak P ressure trial is to be conducted in 14 tertiary neonatal intensive care units in China. A total of 600 preterm infants born with gestational age between 25 0/7 and 31 6/7 weeks and with a primary diagnosis of RDS will be involved in the study. Infants will be randomized to the LISA or LPPSA group when surfactant therapy is indicated. Primary outcomes include mortality, severity of bronchopulmonary dysplasia at 36 weeks of postmenstrual age (PMA), and mechanical ventilation (MV) in the first 72 h of life. Secondary outcomes include the days of MV, duration of all sorts of non-invasive respiratory support, fraction of inspired oxygen, oxygen saturation before and after surfactant administration, and time required to perform the procedure for surfactant administration. The incidence of comorbidities, including retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), hemodynamically significant patent ductus arteriosus (hsPDA), pneumothorax, and massive pulmonary hemorrhage within 48 h of surfactant administration, and the failure rates of each technique will be determined. Discussion Data from recent systematic review and meta-analysis have suggested a possible improvement in outcomes of preterm infants with RDS by the LISA technique. However, robust evidence is lacking. Why LISA plays a potential role in reducing respiratory morbidity, mainly BPD in preterm infants, remains unclear. The possible explanations are the active and uninterrupted delivery of continuous positive airway pressure during the LISA procedure and the avoidance of complications caused by intubation and relatively high pressure/volume ventilation following surfactant administration. We hypothesized that LISA’s effectiveness lies mainly in avoiding relatively high-pressure positive ventilation immediately following surfactant administration. Thus, this multicenter randomized controlled trial will focus on issues of endotracheal intubation and the pressure/volume used during conventional surfactant administration. The effectiveness, safety and comorbidities of preterm infants following LISA or LPPSA will be evaluated. Trial registration Chinese Clinical Trial Registry: ChiCTR1900020970 . Registered on 23 January 2019.

Expression of Concern for Comparison of the Efficacy of Three Natural Surfactants in the Treatment of Respiratory Distress Syndrome Among Neonates: A Randomized Controlled Trial : e5743]

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial

Comparative biophysical study of clinical surfactants using constrained drop surfactometry

Expression of concern

Comparing the Effects of Two Surfactant Administration Methods: Minimally Invasive Surfactant Therapy (MIST) with Intubation (INSURE) in Infants with Respiratory Distress Syndrome

[Efficacy of Minimally Invasive Pulmonary Surfactant Administration in Preterm Infants with Neonatal Respiratory Distress Syndrome: a Multicenter Clinical Trial].

Retracted: Effects of Pulmonary Surfactant Combined with Noninvasive Positive Pressure Ventilation on KRT-14 and ET-1 Levels in Peripheral Blood and Therapeutic Effects in Neonates with Respiratory Distress Syndrome

Minimally Invasive Surfactant Therapy Vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants with Respiratory Distress Syndrome

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model

[For or against the early use of nasal continuous positive pressure and exogenous surfactant in hyaline membrane disease. Physiopathologic arguments]

Intratracheal Instillation of Corticosteroids Using Surfactant As a Vehicle for the Prevention of Chronic Lung Disease in Preterm Infants with Respiratory Distress Syndrome

In Vitro Characterization and in Vivo Comparison of the Pulmonary Outcomes of Poractant Alfa and Calsurf in Ventilated Preterm Rabbits

Early Immunomodulatory Effects of Different Natural Surfactant Preparations in Preterms With Respiratory Distress

A Comparative Study of the Efficacy and Safety of High-Flow Nasal Cannula and Nasal Continuous Positive Airway Pressure in Neonatal Respiratory Distress Syndrome

Less Invasive Surfactant Administration Compared to Intubation, Surfactant, Rapid Extubation Method in Preterm Neonates: An Umbrella Review

A Combination of Short and Simple Surfactant Protein B and C Analogues as a New Synthetic Surfactant: In Vitro and Animal Experiments

Minimally Invasive Surfactant Administration for the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter Randomized Study in China

Surfactants and the importance of informed consent: Nurturing culturally competent care in healthcare settings

Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant